FDA Publishes List of Generic-Ready NDAs, as Action Plan to Boost Competition Takes Shape

The FDA implemented a new policy to expedite generic drug reviews in areas of limited competition, and published a list of off-patent branded drugs with no approved alternatives, as the first steps in the agency’s action plan to help lower the costs of prescription drugs.
Source: Drug Industry Daily